Main Uses and Therapeutic Benefits

Methotrexate is a systemic medication used primarily to manage chronic inflammatory and autoimmune conditions, as well as certain types of oncological diseases. Its therapeutic value lies in its ability to modulate the immune response and slow the rapid division of specific cells.

Rheumatoid Arthritis

Methotrexate is widely considered a foundational therapy for rheumatoid arthritis. It works by reducing the activity of the immune system that causes joint inflammation. The primary goals of treatment in this context are:

• Alleviating joint pain and swelling.
• Reducing stiffness, particularly in the morning.
• Slowing the progression of joint damage and preserving physical function.

Psoriasis and Psoriatic Arthritis

For patients with severe, recalcitrant psoriasis that does not respond to topical treatments, Methotrexate helps manage the excessive production of skin cells. Benefits include:

• Reduction in the thickness and scaling of skin plaques.
• Improvement in skin appearance and comfort.
• Management of joint inflammation associated with psoriatic arthritis.

Other Autoimmune Conditions

The medication is also utilized in the management of several other inflammatory disorders, including:

• Juvenile Idiopathic Arthritis: To help control systemic inflammation in children.
• Systemic Lupus Erythematosus: To manage skin and joint manifestations when other therapies are insufficient.
• Inflammatory Bowel Disease: Sometimes used to maintain remission in conditions like Crohn's disease.

Oncology

In higher doses, Methotrexate acts as a chemotherapeutic agent. It interferes with the growth of certain cancer cells, making it effective in treating:

• Acute lymphoblastic leukemia.
• Non-Hodgkin lymphoma.
• Osteosarcoma.
• Trophoblastic tumors.

Mechanisms of Benefit

The clinical benefits of Methotrexate stem from its role as a folate antimetabolite. By inhibiting specific enzymes, it reduces the synthesis of DNA and RNA required for cell replication and suppresses the release of inflammatory cytokines. This dual action helps stabilize the body's immune environment and prevents the over-proliferation of tissues that drive chronic disease symptoms.

Regulatory References

1. NIH MedlinePlus guidance

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults with approved indications such as rheumatoid arthritis, severe psoriasis, or specific cancers.
• Pediatric patients for conditions like polyarticular juvenile idiopathic arthritis or acute lymphoblastic leukemia.

Populations for whom use is contraindicated:

• Patients who are pregnant or breastfeeding (for non-neoplastic diseases, Methotrexate is an established human teratogen).
• Patients with severe hepatic impairment (e.g., severe liver disease or alcoholism).
• Patients with severe renal impairment (creatinine clearance less than 30 mL/ min).
• Patients with pre-existing significant blood disorders (e.g., bone marrow hypoplasia, severe anemia).
• Patients with active acute or chronic infections or immunodeficiency syndromes.
• Patients with active peptic ulcer disease or ulcerative stomatitis.

Age-related eligibility rules:

• Children under 3 years old are contraindicated for treatment of polyarticular juvenile idiopathic arthritis.
• Older adults require close monitoring due to potential age-related decline in organ function.

Eligibility-related restrictions:

• Both female and male patients of reproductive potential must use effective contraception during and for a specified period after treatment.

Interactions with other medicines and products

The interaction profile of Methotrexate is defined by official regulatory documentation, primarily concerning substances that affect its clearance or contribute to additive toxicity.

Documented Interaction Patterns

Category	Interacting Substances/Conditions (Official)
Exposure Elevation	NSAIDs, Salicylates, Penicillins, Probenecid, Sulfonamides, Proton Pump Inhibitors (PPIs).
Additive Toxicity	Alcohol, Trimethoprim/Sulfamethoxazole, Radiotherapy, other Hepatotoxic Agents.
Antagonism	Folic acid/Folate supplements (may reduce efficacy in neoplastic conditions).

Official Restrictions and Cautions

Exposure-Altering Interactions: The coadministration of NSAIDs and Salicylates may lead to severe adverse reactions, as regulatory documents state these substances reduce the renal clearance of Methotrexate, increasing its concentration in the body. Similarly, Penicillins and Probenecid are officially documented to elevate Methotrexate exposure by inhibiting its renal elimination. PPIs are also noted to elevate serum levels, particularly at high doses.

Additive Toxicity: The simultaneous use of alcohol is officially restricted due to a severe, compounding risk of hepatotoxicity. Coadministration with Trimethoprim/Sulfamethoxazole is officially cautioned against due to the risk of severe bone marrow suppression from an additive anti-folate effect.

Population-Specific Cautions: Official labeling notes that clearance is reduced, increasing the risk of toxicity, in patients with impaired renal function or existing fluid accumulations such as ascites or pleural effusions.

Folate Antagonism and Suppression of Cell Proliferation

The molecule acts as a structural folate antagonist, competitively inhibiting the enzyme Dihydrofolate Reductase (DHFR). This molecular blockade disrupts the synthesis of DNA and RNA by preventing the formation of essential folate cofactors. This action selectively suppresses the rapid division and growth of key immune cells, such as activated lymphocytes, which provides the basis for a suppressive effect on the immune system.

Indirect Immunomodulation via the Adenosine Pathway

A separate, significant mechanism involves the drug's active metabolites inhibiting the enzyme AICART, leading to the accumulation and release of Adenosine into the extracellular space. Adenosine acts as an endogenous anti-inflammatory mediator, activating specific cell receptors to dampen immune responses and reduce the systemic release of inflammatory chemicals (cytokines), which leads to a reduction in inflammatory signals at the cellular level.

How Methotrexate (MTX) is Used: Administration Guidelines

Methotrexate administration is structured according to specific clinical protocols. The method, frequency, and dose are critical factors that depend on the medical condition being addressed.

---

Approved Routes and Forms

MTX is utilized through various routes to achieve systemic or targeted effects, requiring specific formulations:

Route	Primary Use Context	Formulation Note
Oral (PO)	Low-dose, chronic conditions (RA, Psoriasis)	Tablets (e.g., 2.5 mg, 7.5 mg)
Parenteral	Autoimmune conditions, various oncology protocols	Intramuscular (IM), Subcutaneous (SC), Intravenous (IV)
Intrathecal (IT)	CNS-directed therapy (e.g., meningeal leukemia)	Must be preservative-free sterile solution

---

Essential Dosing and Frequency Rules

For chronic inflammatory conditions, the core principle is once-weekly dosing to manage the drug's effect on the body. This frequency is a distinct characteristic of the treatment schedule.

• Rheumatoid Arthritis & Psoriasis: The starting dose is typically 7.5 mg and is adjusted to the lowest effective maintenance dose, generally not exceeding 20 mg weekly for oral use. The weekly dose may be taken as a single administration or split into three doses taken 12 hours apart over a 36-hour period.
• Oncology: Dosing is calculated based on body surface area (mg/m²) and administered according to specialized, defined cyclic regimens, such as high-dose IV infusion protocols.

---

Administration Conditions and Adjustments

Oral tablets are generally taken with or without food. Administration occurs under the supervision of a physician experienced in antimetabolite therapy.

Dose adjustments are required for specific patient groups:

• Renal Impairment: Dose reduction or discontinuation is necessary due to changes in drug clearance.
• Pediatric Dosing: For Juvenile Idiopathic Arthritis (pJIA), the dosage is calculated based on 10 mg/m² once weekly via intramuscular or subcutaneous routes.

Research evidence / Overview of studies for Метотрексат

---

Evidence for use in Low Back Pain (Chronic)

Studies have evaluated the use of Метотрексат in individuals with chronic low back pain, a condition characterized by functional limitations and symptoms that may vary in intensity. This involved short-term randomized controlled trials (RCTs) and observational settings evaluating daily-life functioning. The studies monitored outcomes related to physical discomfort using various pain scales and looked at outcomes reflecting daily functioning or activity level.

Studies reported patterns related to small to moderate changes in average pain scores in some short-term RCTs compared to control groups. Findings describe patterns observed in the studies, but data show patterns related to limited and heterogeneous short-term outcomes. The evidence is limited concerning the scope of data available beyond a few months, and long-term outcomes are not well characterized.

---

Evidence for use in Migraine (Prophylaxis)

Метотрексат was studied for conditions characterized by episodic manifestations, such as migraines, in research exploring short-term symptom changes. Trials focused on adult populations experiencing recurring headaches. Research examined outcomes describing episodic or acute changes, primarily monitoring changes in the number of migraine headache days per month and the intensity of those episodes.

Studies reported patterns related to changes in the mean number of headache days per month in the observed populations in certain RCTs compared to control groups. Research highlights changes measured during the study period, with some evidence contributing to understanding symptom patterns where patients reported varying patterns of change in monthly headache frequency.

---

Evidence for use in Fibromyalgia

Studies explored patient-reported experiences of fibromyalgia, a condition presenting with cycles of stability and flare-ups and marked by functional limitations. Research describes patterns related to small mean changes observed in the study populations concerning outcomes related to perceived discomfort compared to control groups. Findings were mixed across the available trials, and the research provides insight into short-term changes, not definitive long-term outcomes.

---

What is still uncertain about Метотрексат

Most research examining Метотрексат has concentrated on outcomes measured over defined time intervals, typically less than six months. Research indicates that certainty levels regarding many aspects of the evidence are limited. Evidence quality varies across studies in terms of size and design. Subgroup findings are uncertain, meaning that research provides context but not individual predictions about who may or may not respond. Data for certain special populations, such as pediatric or older adults, remain insufficient across these indications.

Common questions about Метотрексат (FAQ)

---

Q: If I miss my once-weekly dose of Methotrexate, what should I do?

The official product information for Methotrexate does not include a universal instruction for a missed dose. Given the critical importance of the correct weekly frequency, contact with the healthcare provider or prescribing physician is recommended for specific guidance if a dose is missed.

---

Q: What are the long-term effects of taking Methotrexate for many years?

Regulatory documents indicate that extended exposure to Methotrexate over many years is officially associated with an increased risk of liver toxicity, which can include fibrosis and cirrhosis. Official product information emphasizes the need for close and continuous monitoring of liver function during extended therapy.

---

Q: How do NSAIDs and Penicillins interact with Methotrexate?

Official labeling warns that both Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Penicillins can interfere with the body’s ability to clear Methotrexate, leading to elevated levels in the bloodstream. The concurrent use of these combinations may require close clinical and laboratory monitoring due to a heightened risk of toxicity.

---

Q: Is Methotrexate safe to use during breastfeeding?

According to official product information, it is generally advised that patients should not breastfeed while using Methotrexate. This is because the drug can be excreted into breast milk and has the potential to cause serious adverse reactions in an infant.

---

Q: What is the difference between Trexall and Rasuvo?

Trexall and Rasuvo are two different marketed forms of the same active medicine. Trexall is formulated as an oral tablet, while Rasuvo is a solution prepared for subcutaneous injection. The choice between these forms depends on the individual therapeutic needs as determined by a healthcare provider.

---

Q: Why is Methotrexate only given once a week for my condition?

The once-weekly dosing schedule is required for non-neoplastic conditions like arthritis or psoriasis to minimize the risk of severe toxicity. Regulatory warnings highlight that mistaken daily use of the weekly dose has been associated with fatal adverse outcomes.

---

Q: What type of specialist typically prescribes and manages Methotrexate treatment?

Official prescribing information requires that Methotrexate be used only under the supervision of a physician experienced in antimetabolite therapy. In clinical practice, management is often overseen by specialists such as Rheumatologists or Oncologists, depending on the condition being treated.

---

Q: How quickly will I start to feel the effects of Methotrexate for my arthritis?

Methotrexate is a disease-modifying drug with a delayed effect. Clinical studies indicate that initial therapeutic effects for conditions like rheumatoid arthritis, such as a reduction in joint swelling and tenderness, may begin to be seen after 3 to 6 weeks of starting treatment.

Storage and Disposal Requirements for Methotrexate

Methotrexate must be stored at Controlled Room Temperature (CRT), typically maintained between 20 C to 25 C (68 F to 77 F). The medication must be protected from light and moisture and should not be stored in environments like a bathroom. To ensure safety, Methotrexate must be stored out of the reach of children and kept in its original, tightly closed container.

In-Use Stability and Disposal

Item	Requirement
In-Use Stability	Preserved multiple-dose injection vials must be used within 30 days of first puncture and stored refrigerated (2 C to 8 C).
Disposal Rule	Unused or expired product must be disposed of according to local regulations or a drug take-back program.

Methotrexate is considered a cytotoxic agent. It must not be flushed down the toilet or poured down a drain, and disposal must follow specific procedures for hazardous medicinal products or cytotoxic waste.